https://chrysbio.com/chrysalis-biotherapeutics-receives-10-4-million-from-barda-to-continue-development-of-tp508-as-a-nuclear-countermeasure/
Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a...
Oct 11, 2021 - Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of treatments for serious...